A voluntary agreement between the Government and the pharmaceutical industry.
The relationship between the pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery of life-enhancing and life-saving medicines.
The Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have welcomed the publication of "Continuity in the availability of goods for the EU and the UK", published today by the UK Government's Department for Exiting the European Union.
As a membership organisation we work with our member companies, and the expertise of the specialists they employ, to develop and present our points of view to UK and European governments, the public and to other stakeholders.
Deepak Khanna talks about his roles as both Managing Director at MSD and also as the new President of the ABPI in this pharmaphorum interview.
00:15 – The inspiration behind becoming ABPI President.
01:19 – The achievements Deepak wishes to fulfil during his tenure at the ABPI.
02:44 – Deepak’s unique experience to bring to the role.
04:19 – How Deepak balances his time and energy between the two roles.
06:06 – How does pharma work with other stakeholders to define value?
07:10 – Views on keeping the UK competitive as a research and commercial pharma environment.
08:58 – Deepak addresses the challenging issue of trust between pharma, healthcare providers and patients.